Clinical Trials

MyeloidOther hematologic neoplasm

6 enrolled

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT04454658 2025-07-16

Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

21 enrolled

Myeloid

Neoplasms, Primary Myelofibrosis

NCT05222984 2025-05-30

Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax

Other hematologic neoplasm

17 enrolled

Leukemia, Myeloid, Acute

NCT00788684 2025-02-20

Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers

29 enrolled

Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Hematologic Neoplasms

NCT04041050 2025-02-14

A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

MyeloidOther hematologic neoplasm

85 enrolled

Myeloproliferative Disorders, Neoplasms, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT02143401 2024-11-22

Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors

29 enrolled

Gastrointestinal

Fibrosis, Hepatitis B, Hepatitis C, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms

NCT05358639 2024-11-18

Combination of Olaparib and Navitoclax in Women with HGSC and TNBC

36 enrolled

BreastGynecologic

Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT04480086 2023-08-29

Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis

Phase 1 Terminated

1 enrolled

Myeloid

Neoplasms, Primary Myelofibrosis

NCT03181126 2021-10-14

A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma

69 enrolled

Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00878449 2018-06-06

A Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With Cancer

12 enrolled

Solid Tumors

NCT00887757 2017-11-21

Safety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects With Solid Tumors

46 enrolled

Solid Tumors

NCT00891605 2017-11-21

Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors

19 enrolled

Solid Tumors

NCT00982566 2017-11-21

Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With Cancer

37 enrolled

Lymphoid Malignancy

NCT01121133 2017-11-21

A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax

12 enrolled

Lymphoid

Lymphoma

NCT01009073 2017-11-20

A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects

51 enrolled

Solid Tumors

NCT00868413 2013-06-07

Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

32 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00888108 2012-05-22

Safety Profile, MTD, and PK Profile Studies of ABT-263 When Administered in Combination With Standard and Weekly Regimens of Docetaxel in Subjects With Cancer

41 enrolled

Solid Tumor

NCT01021358 2010-12-20

A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).

12 enrolled

Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00743028 2010-10-07

Assess the Oral Bioavailability of New ABT-263 Formulations

36 enrolled